Proactive vs. Reactive Pain Control in IBD

Condition: Inflammatory bowel disease

Eligibility

Key Inclusion Criteria

  • Adults with confirmed inflammatory bowel disease (IBD) diagnosis
  • Admitted for IBD-related complaint

Key Exclusion Criteria

  • Admitted for non-IBD complaint
  • Surgery in the last 30 days
  • Alternative GI diagnosis determined
  • Pediatric or pregnant

Full Study Name

Reactive vs. Proactive Pain Control in Patients With Inflammatory Bowel Disease (IRB no. 50742)

Summary

This study focuses on patients who were admitted to the hospital for an inflammatory bowel disease (IBD)-related complaint and who may experience pain during hospitalization. The purpose of the study is to determine whether a proactive, IBD-specific, pain medication protocol is better than the reactive approach to managing pain in hospitalized adults with IBD. The proactive protocol is a set of medications with strong evidence to work well in treating IBD-related pain. The reactive approach is non-specific, which means that the doctor chooses the medication without a pre-set (recommended) list. Researchers will compare patient-reported pain scores, patient activity/movement and opioid consumption in each group to evaluate which approach is more effective.

Participants will be randomly assigned to one of two study groups. The physicians of patients in the PROACTIVE standard-of-care group will have access to an IBD-specific medication guideline to treat pain. Any physician can deviate from this protocol to add, remove or substitute any medication. In the REACTIVE standard-of-care group, patients may be prescribed various medications, depending on the preference of the physician and patient. The only difference between the two groups is that the doctors in the REACTIVE group will not be given the IBD-specific medication guideline.

Principal Investigator

Gil Melmed, MD

Contact
Melissa Hampton
Phone: 310‐423‐0035
Email: melissa.hampton@cshs.org